Efficacy and safety of semaglutide: real-world tertiary care experience from Saudi Arabia
BACKGROUND: Semaglutide, a glucagon-like peptide-1, is an effective antidiabetic drug promoting weight loss and providing cardiovascular protection. The original trials did not include participants from Saudi Arabia; hence, the study's findings are expected to be useful. OBJECTIVES: Explore the...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
King Faisal Specialist Hospital and Research Centre
2024-11-01
|
| Series: | Annals of Saudi Medicine |
| Online Access: | http://www.annsaudimed.net/doi/10.5144/0256-4947.2024.361 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846101546842980352 |
|---|---|
| author | Muhammad Imran Butt Khalid Mania Alkhalifah Muhammad Riazuddin Saud Mohammed Almuammar Salman Mohammed Almuammar Ghayda Abdulkader Alhifthi Fahad Wali Ahmed Samia Mohamed Al Hashim Najeeb Waheed |
| author_facet | Muhammad Imran Butt Khalid Mania Alkhalifah Muhammad Riazuddin Saud Mohammed Almuammar Salman Mohammed Almuammar Ghayda Abdulkader Alhifthi Fahad Wali Ahmed Samia Mohamed Al Hashim Najeeb Waheed |
| author_sort | Muhammad Imran Butt |
| collection | DOAJ |
| description | BACKGROUND: Semaglutide, a glucagon-like peptide-1, is an effective antidiabetic drug promoting weight loss and providing cardiovascular protection. The original trials did not include participants from Saudi Arabia; hence, the study's findings are expected to be useful. OBJECTIVES: Explore the efficacy, safety, and favorable effects of once-weekly subcutaneous semaglutide (1 mg) in patients with type 2 diabetes and those who received it as an off-license prescription without having diabetes. DESIGN: Retrospective review of medical records. SETTING: Department of medicine at our institution. PATIENTS AND METHODS: This retrospective observational study evaluated patients receiving the glucagon-like peptide-1 analog semaglutide, with the trade name Ozempic. The weight, height, body mass index, blood pressure, and laboratory data, including serum creatinine and hemoglobin A1c (HbA1c) levels and urine albumin/creatinine ratio, were recorded. Moreover, any history of medical comorbidities, such as cardiovascular diseases, cerebrovascular diseases, and heart failure, was documented before and after drug administration. MAIN OUTCOME MEASURES: Glycemic and weight loss efficacy SAMPLE SIZE: 1007 patients RESULTS: The median age of the patients was 57.0 years, comprising 60.28% females. Among them, 955 and 442 patients received the medication for at least 3 and 6 months, respectively. Our results show a 4.4% weight loss and 0.4% improvement in HBA1c in patients with diabetes. Similar results were observed in the patients without diabetes in terms of weight along with a significant decrease in diastolic blood pressure. Our results also show stability in the serum creatinine and urine albumin creatinine ratio. The drug was equally effective in males and females. CONCLUSION: Treatment with once-weekly subcutaneous semaglutide (1 mg) led to clinically significant weight loss and improved HbA1c level and cardiometabolic risk factors such as blood pressure. LIMITATIONS: Retrospective design. |
| format | Article |
| id | doaj-art-49f8b3e5aafc4f3e892deeec8ee72448 |
| institution | Kabale University |
| issn | 0256-4947 0975-4466 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | King Faisal Specialist Hospital and Research Centre |
| record_format | Article |
| series | Annals of Saudi Medicine |
| spelling | doaj-art-49f8b3e5aafc4f3e892deeec8ee724482024-12-29T08:40:14ZengKing Faisal Specialist Hospital and Research CentreAnnals of Saudi Medicine0256-49470975-44662024-11-0144636136810.5144/0256-4947.2024.361Efficacy and safety of semaglutide: real-world tertiary care experience from Saudi ArabiaMuhammad Imran Butt0Khalid Mania Alkhalifah1Muhammad Riazuddin2Saud Mohammed Almuammar3Salman Mohammed Almuammar4Ghayda Abdulkader Alhifthi5Fahad Wali Ahmed6Samia Mohamed Al Hashim7Najeeb Waheed8From the Department of Medicine, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi ArabiaFrom the Department of Medicine, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi ArabiaFrom the Department of Medicine, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi ArabiaFrom the Department of Medicine, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi ArabiaFrom the Department of Medicine, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi ArabiaFrom the Department of Medicine, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi ArabiaFrom the Department of Medicine, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi ArabiaFrom the Department of Biostatistics, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi ArabiaFrom the Department of Endocrinology, Imperial College London Diabetes Centre, Al Ain, Abu Dhabi, United Arab EmiratesBACKGROUND: Semaglutide, a glucagon-like peptide-1, is an effective antidiabetic drug promoting weight loss and providing cardiovascular protection. The original trials did not include participants from Saudi Arabia; hence, the study's findings are expected to be useful. OBJECTIVES: Explore the efficacy, safety, and favorable effects of once-weekly subcutaneous semaglutide (1 mg) in patients with type 2 diabetes and those who received it as an off-license prescription without having diabetes. DESIGN: Retrospective review of medical records. SETTING: Department of medicine at our institution. PATIENTS AND METHODS: This retrospective observational study evaluated patients receiving the glucagon-like peptide-1 analog semaglutide, with the trade name Ozempic. The weight, height, body mass index, blood pressure, and laboratory data, including serum creatinine and hemoglobin A1c (HbA1c) levels and urine albumin/creatinine ratio, were recorded. Moreover, any history of medical comorbidities, such as cardiovascular diseases, cerebrovascular diseases, and heart failure, was documented before and after drug administration. MAIN OUTCOME MEASURES: Glycemic and weight loss efficacy SAMPLE SIZE: 1007 patients RESULTS: The median age of the patients was 57.0 years, comprising 60.28% females. Among them, 955 and 442 patients received the medication for at least 3 and 6 months, respectively. Our results show a 4.4% weight loss and 0.4% improvement in HBA1c in patients with diabetes. Similar results were observed in the patients without diabetes in terms of weight along with a significant decrease in diastolic blood pressure. Our results also show stability in the serum creatinine and urine albumin creatinine ratio. The drug was equally effective in males and females. CONCLUSION: Treatment with once-weekly subcutaneous semaglutide (1 mg) led to clinically significant weight loss and improved HbA1c level and cardiometabolic risk factors such as blood pressure. LIMITATIONS: Retrospective design.http://www.annsaudimed.net/doi/10.5144/0256-4947.2024.361 |
| spellingShingle | Muhammad Imran Butt Khalid Mania Alkhalifah Muhammad Riazuddin Saud Mohammed Almuammar Salman Mohammed Almuammar Ghayda Abdulkader Alhifthi Fahad Wali Ahmed Samia Mohamed Al Hashim Najeeb Waheed Efficacy and safety of semaglutide: real-world tertiary care experience from Saudi Arabia Annals of Saudi Medicine |
| title | Efficacy and safety of semaglutide: real-world tertiary care experience from Saudi Arabia |
| title_full | Efficacy and safety of semaglutide: real-world tertiary care experience from Saudi Arabia |
| title_fullStr | Efficacy and safety of semaglutide: real-world tertiary care experience from Saudi Arabia |
| title_full_unstemmed | Efficacy and safety of semaglutide: real-world tertiary care experience from Saudi Arabia |
| title_short | Efficacy and safety of semaglutide: real-world tertiary care experience from Saudi Arabia |
| title_sort | efficacy and safety of semaglutide real world tertiary care experience from saudi arabia |
| url | http://www.annsaudimed.net/doi/10.5144/0256-4947.2024.361 |
| work_keys_str_mv | AT muhammadimranbutt efficacyandsafetyofsemaglutiderealworldtertiarycareexperiencefromsaudiarabia AT khalidmaniaalkhalifah efficacyandsafetyofsemaglutiderealworldtertiarycareexperiencefromsaudiarabia AT muhammadriazuddin efficacyandsafetyofsemaglutiderealworldtertiarycareexperiencefromsaudiarabia AT saudmohammedalmuammar efficacyandsafetyofsemaglutiderealworldtertiarycareexperiencefromsaudiarabia AT salmanmohammedalmuammar efficacyandsafetyofsemaglutiderealworldtertiarycareexperiencefromsaudiarabia AT ghaydaabdulkaderalhifthi efficacyandsafetyofsemaglutiderealworldtertiarycareexperiencefromsaudiarabia AT fahadwaliahmed efficacyandsafetyofsemaglutiderealworldtertiarycareexperiencefromsaudiarabia AT samiamohamedalhashim efficacyandsafetyofsemaglutiderealworldtertiarycareexperiencefromsaudiarabia AT najeebwaheed efficacyandsafetyofsemaglutiderealworldtertiarycareexperiencefromsaudiarabia |